Interferons: interferon alfa-2b (Intron A®); peginterferon alfa-2a (Pegasys®) | Nucleotide or nucleoside analogues: Preferred agents: Entecavir (Baraclude®) 0.5–1 milligram PO daily Tenofovir (Viread®) 300 milligrams PO daily Alternate agents: Adefovir (Hepsera®) 10 milligrams PO daily Lamivudine (Epivir-HBV®) 100 milligrams PO daily Telbivudine (Tyzeka®) 600 milligrams PO daily | Interferons: Products for hepatitis B: Interferon alfa-2a (Roferon®) Peginterferon alfa-2b (Pegintron®) Interferon alfacon-1 (Infergen®) | Ribavirin (CoPegus®, Rebetol®) 800–1400 milligrams PO every day depending upon hepatitis C virus genotype and body weight | Enzyme inhibitors: Boceprevir (Victrelis®) 800 milligrams PO three times daily with food Simeprevir (Olysio®) 150 milligrams PO once daily with food Sofosbuvir (Sovaldi®) 400 milligrams PO once daily with or without food Sofosbuvir 400mg + ledipasvir 90mg (Harvoni®) one tablet PO once daily with or without food |
Mechanism: immunostimulant; activates cytolytic T cells against infected hepatocytes Adverse effects: flu-like syndrome, nausea, diarrhea, fatigue, depression, myelosuppression | Mechanism: inhibitor of viral DNA polymerase Adverse effects: headache, fatigue, nausea, asthenia, abdominal pain and distention, insomnia, lactic acidosis, hepatomegaly, increased creatinine | Mechanism and adverse effects: See Hepatitis B | Mechanism: nucleoside analogue, inhibits hepatitis C virus polymerase Adverse effects: hemolytic anemia and pancytopenia, allergic reactions, dyspnea, pneumonitis, bacterial infections | Mechanism: boceprevir and simeprevir inhibit NS3/4A protease; sofosbuvir inhibits RNA polymerase Adverse effects: anemia, nausea, fatigue, headache, rash, pruritus ledipasvir inhibits NS5A protein |